SHP-1 is strongly activated on CD8+ nonlytic tumor-infiltrating lymphocytes (TILs), co-localizes with Lck on nonlytic TILs, and inhibiting SHP-1 on lytic TILs overcomes the inhibition of TIL cytolysis by tumors. The gene discussed is LCK; the disease is neoplasm.